PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23922192-8 2013 Two studies (n = 288) assessed "responders" and showed a significant difference between TD buprenorphine and placebo in all three doses of TD buprenorphine, 35.5, 52.5, or 70 mug/h (RR 1.74, 95 % CI 1.31-2.32; I (2) 0 %); the numbers-needed-to-treat was 5.8 (3.9-11). Buprenorphine 91-104 ribonucleotide reductase catalytic subunit M1 Homo sapiens 182-186 17210079-12 2007 People allocated to buprenorphine had fewer visits to professional carers during detoxification and more were abstinent at three months (10 vs 4, RR 1.55 CI 0.96-2.52) and six months post detoxification (7 vs 3, RR 1.45 CI 0.84-2.49). Buprenorphine 20-33 ribonucleotide reductase catalytic subunit M1 Homo sapiens 146-150 17210079-12 2007 People allocated to buprenorphine had fewer visits to professional carers during detoxification and more were abstinent at three months (10 vs 4, RR 1.55 CI 0.96-2.52) and six months post detoxification (7 vs 3, RR 1.45 CI 0.84-2.49). Buprenorphine 20-33 ribonucleotide reductase catalytic subunit M1 Homo sapiens 212-216